172 related articles for article (PubMed ID: 30553007)
1. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
[TBL] [Abstract][Full Text] [Related]
2. Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity.
Wang H; Wu J; Xu L; Xie K; Chen C; Dong Y
Chem Commun (Camb); 2017 Feb; 53(17):2618-2621. PubMed ID: 28195282
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles.
Xu G; Shi H; Ren L; Gou H; Gong D; Gao X; Huang N
Int J Nanomedicine; 2015; 10():2051-63. PubMed ID: 25844036
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy.
Gao S; Zhang W; Wang R; Hopkins SP; Spagnoli JC; Racin M; Bai L; Li L; Jiang W; Yang X; Lee C; Nagata K; Howerth EW; Handa H; Xie J; Ma Q; Kumar A
ACS Nano; 2020 Feb; 14(2):1468-1481. PubMed ID: 31939662
[TBL] [Abstract][Full Text] [Related]
5. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer.
Li Y; Duo Y; Bao S; He L; Ling K; Luo J; Zhang Y; Huang H; Zhang H; Yu X
Int J Nanomedicine; 2017; 12():6239-6257. PubMed ID: 28894364
[TBL] [Abstract][Full Text] [Related]
6. DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma.
Hale SJM; Perrins RD; Garcı A CE; Pace A; Peral U; Patel KR; Robinson A; Williams P; Ding Y; Saito G; Rodriguez MÁ; Perera I; Barrientos A; Conlon K; Damment S; Porter J; Coulter T
Bioconjug Chem; 2019 Mar; 30(3):703-713. PubMed ID: 30582799
[TBL] [Abstract][Full Text] [Related]
7. Self-assembling poly(ethylene glycol)-block-polylactide-cabazitaxel conjugate nanoparticles for anticancer therapy with high efficacy and low in vivo toxicity.
Shuai Q; Zhao G; Lian X; Wan J; Cen B; Zhang W; Liu J; Su W; Wang H
Int J Pharm; 2020 Jan; 574():118879. PubMed ID: 31770581
[TBL] [Abstract][Full Text] [Related]
8. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.
Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T
Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
[TBL] [Abstract][Full Text] [Related]
10. Transforming a highly toxic agent DM1 into injectable safe nanomedicines
Huang J; Song S; Wang M; Wang H
Nanoscale; 2023 Jun; 15(23):10110-10124. PubMed ID: 37255385
[TBL] [Abstract][Full Text] [Related]
11. A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy.
Meng H; Zou Y; Zhong P; Meng F; Zhang J; Cheng R; Zhong Z
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28464449
[TBL] [Abstract][Full Text] [Related]
12. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
[TBL] [Abstract][Full Text] [Related]
13. Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer.
Yu X; Wu H; Hu H; Dong Z; Dang Y; Qi Q; Wang Y; Du S; Lu Y
Drug Deliv; 2020 Dec; 27(1):100-109. PubMed ID: 31870183
[No Abstract] [Full Text] [Related]
14. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
16. Technology evaluation: C242-DM1, ImmunoGen Inc.
Smith S
Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
[TBL] [Abstract][Full Text] [Related]
17. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy.
Wang YQ; Ji MY; Wang C
Int J Pharm; 2020 May; 582():119331. PubMed ID: 32289484
[TBL] [Abstract][Full Text] [Related]
19. Barbaloin loaded polydopamine-polylactide-TPGS (PLA-TPGS) nanoparticles against gastric cancer as a targeted drug delivery system: Studies in vitro and in vivo.
Wang YR; Yang SY; Chen GX; Wei P
Biochem Biophys Res Commun; 2018 Apr; 499(1):8-16. PubMed ID: 29534962
[TBL] [Abstract][Full Text] [Related]
20. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
